In conclusion, this study discovered that HIBCH and MGME1 are new biomarkers of AD, and miR‐922/MGME1 axis may contribute to the pathophysiology of AD, could act as the diagnostic and treatment target for AD. This evidence concerns the gene HIBCH and Alzheimer disease.